Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-10

Prelude Therapeutics (PRLD)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,348,000
Krishna Vaddi total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
99.6%
Say-on-pay support, latest vote
Companies that benchmark against PRLD
4 companies name PRLD as a compensation peer

Each company listed discloses PRLD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PRLD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Krishna Vaddi$615,441$0$0$412,744$309,465$0$10,350$1,348,000
Chief Executive Officer
Bryant Lim477,50000166,347193,200010,350847,397
Chief Legal Officer, Corporate Secretary, and Chief Financial Officer
Peggy Scherle473,41600145,523190,440010,350819,729
Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Krishna Vaddi$1,348,000$2,327,471−979,471
Bryant Lim847,3971,202,912−355,515
Peggy Scherle819,729

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Peggy A. Scherle, Ph. D.OPTION2025-02-04175,000$145,523
Bryant LimOPTION2025-02-04200,000166,347
Krishna Vaddi, Ph.D.OPTION2025-02-04496,000412,744
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Peggy A. Scherle, Ph. D.$0$0$145,5230.0%
Bryant Lim00166,3470.0%
Krishna Vaddi, Ph.D.00412,7440.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Krishna VaddiOption96,2507.2
Krishna VaddiRSU12,9690
Krishna VaddiOption13,66310.58
Krishna VaddiOption239,0634.59
Krishna VaddiOption496,0001.11
Peggy ScherleOption4,16710.58
Bryant LimOption84,3754.59
Peggy ScherleOption39,3757.2
Peggy ScherleOption84,3754.59
Peggy ScherleOption175,0001.11
Bryant LimOption78,1255.93
Bryant LimOption15,1053.86
Bryant LimOption200,0001.11
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation program is designed to attract, retain, and motivate executive officers by providing a balanced mix of base salary, annual cash incentives, and long-term equity awards. Equity-based compensation is viewed as a critical component to align the interests of executives with those of shareholders, rewarding past performance and creating incentives to meet long-term objectives.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantCompensia
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0926,869,142107,50076,11599.6%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0999.6%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Victor SandorIndependent · Nominating and Corporate Governance (Chair)$46,000$148,528$194,528
Paul A. FriedmanIndependent · Nominating and Corporate Governance74,00028,533102,533
David P. BonitaIndependent · Compensation (Chair) · Audit57,50028,53386,033
Paul SchererIndependent · Nominating and Corporate Governance · Compensation24,50057,06681,566
Martin BablerIndependent · Audit · Compensation50,00028,53378,533
Katina DortonIndependent · Audit (Chair)11,30166,26377,564
Krishna VaddiEmployee director0
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$263,301
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$263,301

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Prelude Therapeutics2025Krishna Vaddi$615,441$0$412,744$309,465$1,348,000

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Krishna VaddiDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation”. As printed: 1,348,000. Filing ↗machine: span 557496–557505
2Section 01, Bryant LimDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation”. As printed: 847,397. Filing ↗machine: span 576113–576120
3Section 01, Peggy ScherleDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation”. As printed: 819,729. Filing ↗machine: span 566883–566890
4Section 03, Peggy A. Scherle, Ph. D. OPTIONDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 618997–619004
5Section 03, Bryant Lim OPTIONDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 626949–626956
6Section 03, Krishna Vaddi, Ph.D. OPTIONDEF 14A2026-04-290001193125-26-191532Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 611031–611038
7Section 08, Victor SandorDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 194,528. Filing ↗
8Section 08, Paul A. FriedmanDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 102,533. Filing ↗
9Section 08, David P. BonitaDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 86,033. Filing ↗
10Section 08, Paul SchererDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 81,566. Filing ↗
11Section 08, Martin BablerDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 78,533. Filing ↗
12Section 08, Katina DortonDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 77,564. Filing ↗
13Section 08, Krishna VaddiDEF 14A2026-04-290001193125-26-191532Section “Director Compensation”. As printed: 0. Filing ↗
14Section 06, 2026 voteForm 8-K2026-06-100001193125-26-265835Item 5.07 · say-on-pay result. As reported: 99.6% (votes for as printed: 26,869,142). Filing ↗
15Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
16Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
17Section 09b board cost (computed)ComputedcomputedCash 263,301 + equity 0 + all other 0 = 263,301, summed across the director compensation table rows.machine: formula: Σ = 263,301
18Prelude Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-290001193125-26-191532CEO total compensation as printed in Prelude Therapeutics's own proxy. As printed: 1,348,000. Filing ↗machine: span 557496–557505